Histotripsy is a non-invasive treatment, approved by the Food and Drug Administration (FDA) in 2023, that uses ultrasound energy to destroy liver tumors in a single outpatient procedure. This includes primary liver tumors originating in the liver, or metastasized tumors resulting from another cancer spreading to the liver. Histotripsy is a new option for patients with liver tumors who may not be a candidate for surgery or other traditional therapies.
Histotripsy is a non-invasive treatment, approved by the Food and Drug Administration (FDA) in 2023, that uses ultrasound energy to destroy liver tumors in a single outpatient procedure. This includes primary liver tumors originating in the liver, or metastasized tumors resulting from another cancer spreading to the liver. Histotripsy is a new option for patients with liver tumors who may not be a candidate for surgery or other traditional therapies.
Ochsner LSU Health has welcomed three new physicians to its Monroe team, enhancing access to primary care, sports medicine, and obstetrics and gynecology. These specialists will also contribute to medical education as faculty members at LSU Health Shreveport.
Ochsner LSU Health has expanded its team with the addition of four new physicians, enhancing access to specialized care in the Shreveport-Bossier area. These physicians, who bring expertise in radiology, neonatology, internal medicine, and vascular neurology, will also serve as faculty members at LSU Health Shreveport.
